Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib
Retinol Binding Protein 4 Expression and Its Genetic Variants in Severe Alopecia Areata Treated With Barcitinib.
In the register
The register attaches this trial to Baricitinib (Olumiant) (Eli Lilly), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 1
- Sponsor
- South Valley University
- Participants (registry)
- 120
- Start
- September 2023
- Primary completion
- September 2024
- Study completion
- October 2024
- Last registry update
- August 2024
- Countries
- Egypt
Conditions studied: Alopecia Areata
Interventions: Baricitinib Oral Tablet
Other trials of Baricitinib (Olumiant)
Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study
Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
- NCT07645430Completed
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.